Page last updated: 2024-08-24

thiazolyl blue and Bone Diseases, Metabolic

thiazolyl blue has been researched along with Bone Diseases, Metabolic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baraldi, PG; Bianchini, E; Gambari, R; Lambertini, E; Penolazzi, L; Piva, R; Romagnoli, R1

Other Studies

1 other study(ies) available for thiazolyl blue and Bone Diseases, Metabolic

ArticleYear
N-Arylpiperazine modified analogues of the P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts.
    Journal of biomedical science, 2005, Volume: 12, Issue:6

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acid Phosphatase; Apoptosis; Bone and Bones; Bone Diseases, Metabolic; Caspase 3; Caspases; Cell Nucleus; Cells, Cultured; Enzyme Activation; Enzyme Inhibitors; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-6; Isoenzymes; Models, Chemical; NF-kappa B; Osteoblasts; Osteoclasts; Piperazines; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2X7; Tartrate-Resistant Acid Phosphatase; Tetrazolium Salts; Thiazoles; Time Factors

2005